Literature DB >> 6236165

Effect of ASTA Z 7557 (INN mafosfamide) a precursor of 4-hydroxy-cyclophosphamide on human T-lymphocytes' Fc-receptors and immunoregulatory functions.

J G Saal, M Hadam, F Frank, H Rautenstrauch, P Fritz.   

Abstract

The precursor ASTA Z 7557 of the in vivo active metabolite 4-hydroxy-cyclophosphamide (4OH-Cy) of cyclophosphamide (Cy) was tested for selective effects on human T-lymphocytes' Fc gamma-receptor expression and certain immunoregulatory functions. It has been found that ASTA Z 7557 does not alter the expression of Fc gamma-F- or Fc gamma-I-receptors on the T-cell membrane nor does it exhibit differential toxicity for either T-cell subpopulation. PWM-induced B-cell proliferation is inhibited by ASTA Z 7557, whereas B-cells' Ig-synthesis as well as ConA-driven T-cell proliferation is only blocked with higher doses of the reagent. Final concentrations above 1 microgram/ml may therefore abrogate ConA-induction of suppressor T-lymphocytes. Already ConA-activated suppressor cells of PWM-driven B-cell cultures, however, are not inhibited even with high doses of ASTA Z 7557.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6236165     DOI: 10.1007/bf00232357

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  10 in total

1.  Regulation of delayed-type hypersensitivity. III. Effect of cyclophosphamide on the suppressor cells for delayed-type hypersensitivity to sheep erythrocytes in mice.

Authors:  H K Gill; F Y Liew
Journal:  Eur J Immunol       Date:  1978-03       Impact factor: 5.532

2.  Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE.

Authors:  Z Lando; D Teitelbaum; R Arnon
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

3.  Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Authors:  T Wagner; D Heydrich; T Jork; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

4.  Suppression of human B lymphocyte function by cyclophosphamide.

Authors:  T R Cupps; L C Edgar; A S Fauci
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

5.  Activation and suppression of graft-vs-host reactions by cyclophosphamide.

Authors:  R H Wander; H R Hilgard
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

6.  Nonspecific inhibitor of DNA synthesis elaborated by T acceptor cells. I. Specific hapten- and I-J-driven liberation of an inhibitor of cell proliferation by Lyt-1-2+ cyclophosphamide-sensitive T acceptor cells armed with a product of Lyt-1+2+-specific suppressor cells.

Authors:  M Malkovský; G L Asherson; P Chandler; V Colizzi; M C Watkins; M Zembala
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

7.  Two distinct Fc receptors for IgG on human peripheral T lymphocytes.

Authors:  J G Saal; M R Hadam; H E Feucht; H Rautenstrauch
Journal:  Scand J Immunol       Date:  1982-07       Impact factor: 3.487

8.  T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycyclophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. A direct proof for different sensitivities of lymphocyte subsets to cyclophosphamide.

Authors:  T Diamantstein; E Willinger; J Reiman
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

9.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

10.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.